TREGLY XR Trademark

Trademark Overview


On Monday, September 29, 2025, a trademark application was filed for TREGLY XR with the United States Patent and Trademark Office. The USPTO has given the TREGLY XR trademark a serial number of 99419747. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, February 6, 2026. The TREGLY XR trademark is filed in the Pharmaceutical Products category with the following description:

Anti-diabetic pharmaceuticals
tregly xr

General Information


Serial Number99419747
Word MarkTREGLY XR
Filing DateMonday, September 29, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, February 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesAnti-diabetic pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 29, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressKapolei, HI 96707

Trademark Events


Event DateEvent Description
Monday, September 29, 2025NEW APPLICATION ENTERED
Monday, September 29, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 29, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, February 4, 2026ASSIGNED TO EXAMINER
Friday, February 6, 2026NON-FINAL ACTION WRITTEN
Friday, February 6, 2026NON-FINAL ACTION E-MAILED
Friday, February 6, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords


tregly pharmaceuticals diabetic anti